Get the Stockscreener App
5.44
2.51%
-0.14
After Hours:
5.48
0.04
+0.74%
Humacyte Inc stock is traded at $5.44, with a volume of 1.73M.
It is down -2.51% in the last 24 hours and down -10.08% over the past month.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.
See More
Previous Close:
$5.58
Open:
$5.54
24h Volume:
1.73M
Relative Volume:
0.54
Market Cap:
$655.24M
Revenue:
-
Net Income/Loss:
$-110.78M
P/E Ratio:
-6.2529
EPS:
-0.87
Net Cash Flow:
$-75.59M
1W Performance:
+4.02%
1M Performance:
-10.08%
6M Performance:
+74.92%
1Y Performance:
+85.67%
1-Day Range:
$5.34
$5.745
1-Week Range:
$5.26
$6.43
52-Week Range:
$1.96
$9.97
Humacyte Inc Stock (HUMA) Company Profile
Name
Humacyte Inc
Sector
Industry
Phone
919-313-9633
Address
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-14-23 | Upgrade | Piper Sandler | Underweight → Neutral |
| Jun-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-22 | Downgrade | Piper Sandler | Overweight → Underweight |
| Oct-29-21 | Initiated | Cowen | Outperform |
| Sep-24-21 | Initiated | Oppenheimer | Outperform |
| Sep-22-21 | Initiated | BTIG Research | Buy |
| Sep-16-21 | Initiated | Piper Sandler | Overweight |
View All
Humacyte Inc Stock (HUMA) Latest News
Humacyte's SWOT analysis: HAV tech drives stock's potential amid challenges - Investing.com
Humacyte, Inc. (NASDAQ:HUMA) Short Interest Update - MarketBeat
Humacyte: Surprise PDUFA Delay, Low Cash, Excellent Product - Seeking Alpha
Humacyte, Inc. (HUMA) Increases Yet Falls Behind Market: What Investors Need to Know - Yahoo Finance
Humacyte to Host Virtual KOL Event to Discuss Case Studies on the Use of Acellular Tissue Engineered Vessel (ATEV™) in Vascular Trauma Treatment on September 30, 2024 - The Manila Times
Humacyte to Host Virtual KOL Event to Discuss Case Studies on the Use of Acellular Tissue Engineered Vessel (ATEV™) in Vascular Trauma Treatment on September 30, 2024 - GlobeNewswire Inc.
Deerfield Management Company L.P. Series C Buys New Holdings in Humacyte, Inc. (NASDAQ:HUMA) - MarketBeat
BioAesthetics Welcomes New CEO - MPO-mag
Humacyte (NASDAQ:HUMA) Shares Gap Down to $6.12 - MarketBeat
Humacyte stock falls on plans to sell up to $50M shares to Lincoln Park - MSN
Where are the Opportunities in (HUMA) - Stock Traders Daily
Humacyte: Navigating The FDA Uncertainty And ATEV’s Potential (NASDAQ:HUMA) - Seeking Alpha
How analysts predict Humacyte Inc (HUMA) will perform this quarter? - US Post News
HilleVax Inc (HLVX) can make a big difference with a little luck - SETE News
GILD: 3 Biotech Stocks to Watch as FDA Approvals Roll In - StockNews.com
Humacyte Inc (HUMA) rating initates by H.C. Wainwright - Knox Daily
HilleVax, Inc. (NASDAQ:HLVX) Given Consensus Rating of “Hold” by Analysts - Defense World
420,000 Shares in Humana Inc. (NYSE:HUM) Bought by Baupost Group LLC MA - Defense World
Columbus Hill Capital Management L.P. Has $30.82 Million Holdings in Humana Inc. (NYSE:HUM) - Defense World
Humacyte, Inc. (NASDAQ:HUMA) Stock Holdings Lifted by Bank of New York Mellon Corp - MarketBeat
Cantor Fitzgerald Reaffirms "Overweight" Rating for Humacyte (NASDAQ:HUMA) - MarketBeat
HM Channels Brat For Its A/W 2024 Collection - ELLE India
Urgently Completes Strategic Divestiture of The Floow in Support of Core Business Focus - StockTitan
Humacyte gains US patent for diabetes treatment device - Investing.com
Humacyte Announces Allowance of U.S. Patent Covering BioVascular Pancreas (BVP™) - EIN News
Five Biotech Stocks Soar: Eyes on Halozyme, United Therapeutics, Harmony, Ligand, and ADMA - geneonline
Humacyte, Inc. (HUMA) Is Considered a Good Investment by Brokers: Is That True? - MSN
Humacyte (NASDAQ:HUMA) Shares Up 3.4% - MarketBeat
The Potential Rise in the Price of Aurinia Pharmaceuticals Inc (AUPH) following insiders activity - Knox Daily
Humacyte, Inc. (HUMA) Is Considered a Good Investment by Brokers: Is That True? - Zacks Investment Research
Coherus shares stumble on supply issue - The Pharma Letter
Upward Trajectory: Humacyte Inc (HUMA) Posts a Slidee, Closing at 5.28 - The Dwinnex
Universal Health Services: Stock Has Lots Of Upside Runway (NYSE:UHS) - Seeking Alpha
Humacyte (NASDAQ:HUMA) Trading Down 3.7% - MarketBeat
Analyzing HUMA’s current quarter earnings projections - US Post News
Huggies, Walgreens Partner To Help Families Struggling With Diaper Need - Nonwovens Industry
Humacyte Inc (HUMA) can make a big difference with a little luck - SETE News
DekaBank Deutsche Girozentrale Sells 5,311 Shares of Humana Inc. (NYSE:HUM) - Defense World
VC funding: Huma, Landbase, AceUp, Gestalt Tech - InfotechLead.com
Independent Director of Hilton Worldwide Holdings Judith McHale Buys 219% More Shares - Simply Wall St
(HUMA) Investment Report - Stock Traders Daily
UnitedHealth begins to move away from Humira, joining CVS, Express Scripts - BenefitsPro
Huma Raises $38M to Hyper-scale its Payment Financing (PayFi) Network - StreetInsider.com
Humacyte CEO sells over $2.3 million in company stock - Investing.com India
Humacyte director Sebelius sells shares worth over $28,000 By Investing.com - Investing.com Australia
Humacyte director Sebelius sells shares worth over $28,000 - Investing.com
Humacyte director sells over $2.3 million in company stock - Investing.com
Humacyte director sells over $2.3 million in company stock - Investing.com India
Humacyte director sells over $2.3 million in company stock By Investing.com - Investing.com Canada
Humacyte director Sebelius sells shares worth over $28,000 - Investing.com India
Humacyte CEO sells over $2.3 million in company stock - Investing.com
Humacyte Inc Stock (HUMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):